It was found that PLC-β1-PI3K-AKT signal axis was very important for CCA development and EMT, and AKT can be used as a therapeutic target to overcome the chemotherapy resistance of CCA patients with high PLC-β1 expression, thus inhibiting the growth of tumor and obviously improving the postoperative survival of patients (65). The gene discussed is PLCB1; the disease is cholangiocarcinoma.